semaglutide cease and desist Ozempic's patent problem: how Novo Nordisk lost control of a blockbuster drug. 💉 Demand for GLP-1 weight-loss drugs has exploded, turning Ozempic into a $40bn+ revenue engine for Novo Nordisk. But, despite Novo Nordisk, Eli Lilly Sending

GDP, increased demand for an expensive drug used by many for non-clinically indicated weight loss is likely to have a profound impact on healthcare expenditures, health equity and the overall health status of American patients

Semaglutide starts at 0.25mg weekly with titration up to 2.4mg based on tolerance and efficacy

This can result in possible sepsis with fatal organ damage (3)

The general principle applied to weight-loss medications is that the medication itself may not preclude donation, but the underlying health conditions, treatment response, and overall medical status require comprehensive evaluation

Lancet 2 (7349), 2021

ng thi gip h tr ci thin tnh trng thm mn, l chn lng to, da thm sm vi s kt hp t Glutathione v Niacinamide